Immunotherapy of genitourinary malignancies.

Immunotherapy of genitourinary malignancies.
复制标题

DOI:
10.1155/2012/397267
复制
发表时间:
2012
影响因子:
--
通讯作者:
Azuma H
Azuma H
中科院分区:
医学3区
文献类型:
--
作者:
Inamoto T;Azuma H

文献摘要

参考文献

被引文献

相似文献

大多数癌症患者接受手术、放疗和化疗的联合治疗。尽管最近在局部治疗方面取得了进展,但由于严重的副作用和不完全的长期缓解,转移性疾病的化疗治疗往往不令人满意。因此,评估新的治疗方案是非常有趣的。传统的,随着新的治疗策略靶向免疫系统,抑制泌尿生殖系统(GU)恶性肿瘤。转移性肾细胞癌和非肌肉侵袭性膀胱癌代表了所有人类癌症中最具免疫反应性的类型。本文综述了支持免疫疗法抗癌活性的基本原理和新出现的证据,以对抗GU恶性肿瘤。
Most cancer patients are treated with some combination of surgery, radiation, and chemotherapy. Despite recent advances in local therapy with curative intent, chemotherapeutic treatments for metastatic disease often remain unsatisfying due to severe side effects and incomplete long-term remission. Therefore, the evaluation of novel therapeutic options is of great interest. Conventional, along with newer treatment strategies target the immune system that suppresses genitourinary (GU) malignancies. Metastatic renal cell carcinoma and non-muscle-invasive bladder caner represent the most immune-responsive types of all human cancer. This review examines the rationale and emerging evidence supporting the anticancer activity of immunotherapy, against GU malignancies.
DOI: 10.3322/caac.20006
发表时间: 2009-07-01
影响因子: 254.7
作者:
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者: Thun, Michael J.
DOI: 10.1200/jco.1995.13.6.1404
发表时间: 1995-06-01
影响因子: 45.3
作者:
HERR, HW;SCHWALB, DM;OETTGEN, HF
通讯作者: OETTGEN, HF
DOI: 10.1097/cji.0b013e3181952b1d
发表时间: 2009-02-01
影响因子: 3.9
作者:
Cho, Daniel C.;Puzanov, Igor;McDermott, David F.
通讯作者: McDermott, David F.
DOI: 10.3945/ajcn.2009.27781
发表时间: 2009-10-01
影响因子: 7.1
作者:
Bauer, Florianne;Elbers, Clara C.;van der Schouw, Yvonne T.
通讯作者: van der Schouw, Yvonne T.
DOI: 10.1056/nejmoa1001294
发表时间: 2010-07-29
影响因子: 158.5
作者:
Kantoff, Philip W.;Higano, Celestia S.;Young, J.
通讯作者: Young, J.